Eli Zuckerman
YOU?
Author Swipe
View article: Sclerosing Cholangitis and Multiple Liver Abscesses in a Patient with Thymoma, Myasthenia Gravis, and Immune Deficiency (Good’s Syndrome)
Sclerosing Cholangitis and Multiple Liver Abscesses in a Patient with Thymoma, Myasthenia Gravis, and Immune Deficiency (Good’s Syndrome) Open
BACKGROUND Thymoma is associated with immune deficiencies and can predispose to infections and autoimmune disorders, both of which can lead to hepatobiliary structural disease and infection. CASE REPORT We report the case of a 77-year-old …
View article: Risk of hepatocellular carcinoma and cirrhosis decompensation in a large retrospective cohort of cirrhotic patients with autoimmune hepatitis
Risk of hepatocellular carcinoma and cirrhosis decompensation in a large retrospective cohort of cirrhotic patients with autoimmune hepatitis Open
Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease that can lead to cirrhosis in up to 30% of patients. Cirrhotic patients are at risk of high morbidity and mortality due to cirrhosis decompensation and hepatocellular carci…
View article: The Epidemiology of Hepatitis E in Israel and Potential Risk Factors: A Cross-Sectional Population-Based Serological Survey of Hepatitis E Virus in Northern Israel
The Epidemiology of Hepatitis E in Israel and Potential Risk Factors: A Cross-Sectional Population-Based Serological Survey of Hepatitis E Virus in Northern Israel Open
Hepatitis E Virus (HEV) has gained public health attention as one of the causative agents of viral hepatitis. Our study aimed to provide data about HEV seropositivity in the Israeli general population, including its seroprevalence geograph…
View article: A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease Open
Currently, there are no approved therapies for non-alcoholic steatohepatitis (NASH). The weight loss associated with glucagon-like peptide-1 (GLP-1) receptor agonists has been shown to decrease hepatic inflammation in patients with NASH. I…
View article: Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study Open
Background and Aims: ENHANCE was a phase 3 study that evaluated efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-δ (PPAR) agonist, versus placebo in patients with primary biliary cholangitis with in…
View article: Treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir in chronic hepatitis C genotype 2k/1b.
Treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir in chronic hepatitis C genotype 2k/1b. Open
Aim : Hepatitis C virus (HCV) infection is one of the most prevalent etiologies for liver cirrhosis and hepatocellular carcinoma. As a result of being highly heterogeneous, HCV has seven confirmed major genotypes and 67 confirmed subtype…
View article: Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection
Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection Open
In a pooled analysis of data from 8 trials, we found that 8 weeks of treatment with glecaprevir/pibrentasvir is efficacious and well tolerated in treatment-naïve patients with HCV genotype 1 to 6 infections, with or without cirrhosis.
View article: Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras
Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras Open
Besides seven major hepatitis C virus (HCV) genotypes (GT), a number of intergenotypic recombinant strains have been described. These so-called chimeras combine genetic characteristics of different HCV genotypes.
View article: Delayed Bleeding after Percutaneous Liver Biopsy
Delayed Bleeding after Percutaneous Liver Biopsy Open
Percutaneous liver biopsy (PLB) is a common procedure in patients with liver disease. Bleeding after PLB is rare, with an incidence of 0.35%. Most bleeding complications present within 24 h after biopsy. A 56-year-old woman was admitted to…
View article: Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1. Open
NCT02105454.
View article: Secondary sclerosing cholangitis following major burn
Secondary sclerosing cholangitis following major burn Open
SSC-CIP was diagnosed in 4 consecutive patients hospitalized due to major burn injuries at our Intensive Care Unit (ICU). SSC-CIP was diagnosed when ERCP (n = 1) or MRCP (n = 3) demonstrated irregular intrahepatic bile ducts with multiple …
View article: Strategies to manage hepatitis <scp>C</scp> virus (<scp>HCV</scp>) infection disease burden – volume 2
Strategies to manage hepatitis <span>C</span> virus (<span>HCV</span>) infection disease burden – volume 2 Open
Summary The hepatitis C virus ( HCV ) epidemic was forecasted through 2030 for 15 countries, and the relative impact of two scenarios was considered: (i) increased treatment efficacy while holding the treated population constant and (ii) i…
View article: The present and future disease burden of hepatitis <scp>C</scp> virus (<scp>HCV</scp>) infections with today's treatment paradigm – volume 2
The present and future disease burden of hepatitis <span>C</span> virus (<span>HCV</span>) infections with today's treatment paradigm – volume 2 Open
Summary Morbidity and mortality attributable to chronic hepatitis C virus ( HCV ) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic p…
View article: Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in select countries – volume 2
Historical epidemiology of hepatitis C virus (<span>HCV</span>) in select countries – volume 2 Open
Summary Chronic hepatitis C virus ( HCV ) infection is a leading cause of liver related morbidity and mortality. In many countries, there is a lack of comprehensive epidemiological data that are crucial in implementing disease control meas…